Lazolvan what is it

Posted on by admin

Lazolvan - instructions and price

  • ATX code: R05CB06
  • Release form: tablets, syrup, solution, spray, lozenges

Introduction to instructions for use

1. Pharmacological action

2. indications for use

3. Method of application

Recommended dosage of Lazolvan in the form of syrup for internal use (active substance content - 30 mg per 5 ml):

Table of contents:

  • Patients age 6-12 years: half a teaspoon of the drug up to three times a day;

Recommended dosage of Lazolvan in the form of an oral solution:

  • up to two years of life: 25 drops of the drug twice a day;

In all cases, Lazolvan should be diluted in any liquid and taken with meals.

  • Patients under 6 years of age: 2 ml of the drug for inhalation up to two times a day;

In all cases, the use of Lazolvan is possible using any modern inhalation devices, except the evaporating type.

30 mg of the drug for each kg of body weight, divided into four injections.

4. Side effects

  • Disorders of the digestive system (heartburn, nausea, pain in the stomach, vomiting);

5. Contraindications

  • Use of Lazolvan in the first trimester of pregnancy;

6. During pregnancy and lactation

7. Interaction with other drugs

8. Overdose

9. Release form

Tablets, 30 mg - 20 or 50 pcs.

Syrup for internal use, 15 mg/5 ml - vial. 100 ml or 200 ml; 30 mg/5 ml – vial. 100 ml or 200 ml.

Solution for internal use, 7.5 mg/1 ml - vial. 100 ml.

10. Storage conditions

  • Recommended storage temperature (Lazolvan in solution form) is no more than 25 degrees;

Recommended shelf life for various forms of the drug:

11. Composition

1 lozenge:

  • ambroxol hydrochloride - 15 mg;

1 tablet:

  • ambroxol hydrochloride - 30 mg;

5 ml syrup:

  • ambroxol hydrochloride - 15 or 30 mg;

1 ml solution:

  • ambroxol hydrochloride - 7.5 mg;

12. Conditions for dispensing from pharmacies

— Did you find a mistake? Select it and press Ctrl + Enter

REVIEWS ABOUT THE DRUG Lazolvan

Adding a new review

We recommend reading

Active ingredients

Pharmacological action

Disease class

  • Pneumonia without specifying the pathogen

Pharmacological group

  • Secretolytics and stimulants of motor function of the respiratory tract Secretolytics and stimulants of motor function of the respiratory tract in combinations

IMPORTANT. The information on the site is provided for informational purposes only. Do not self-medicate. At the first sign of disease, consult a doctor.

Source: http://pillsman.org/212-lazolvan.html

Lazolvan - instructions for use, analogs, reviews and release forms (tablets 30 mg, syrup, solution for inhalation, lozenges 15 mg) of a drug for the treatment of cough and bronchitis in adults, children and pregnancy

In this article you can read the instructions for use of the drug Lazolvan. Reviews of site visitors - consumers of this medicine, as well as the opinions of specialist doctors on the use of Lazolvan in their practice are presented. We kindly ask you to actively add your reviews about the drug: whether the medicine helped or did not help get rid of the disease, what complications and side effects were observed, perhaps not stated by the manufacturer in the annotation. Analogues of Lazolvan in the presence of existing structural analogues. Use for the treatment of bronchitis, pneumonia and cough in adults, children, as well as during pregnancy and lactation.

Lazolvan is a mucolytic drug.

Studies have shown that ambroxol (the active ingredient of Lazolvan) increases secretion in the respiratory tract. Enhances the production of pulmonary surfactant and stimulates ciliary activity. These effects lead to increased mucus flow and transport (mucociliary clearance). Increasing mucociliary clearance improves sputum discharge and relieves cough.

Lazolvan is characterized by rapid and almost complete absorption with a linear dose dependence in the therapeutic concentration range. The transition of ambroxol from the blood to tissues when administered orally occurs quickly. The highest concentrations of the active component of the drug are observed in the lungs. Approximately 30% of the dose taken undergoes a first-pass effect through the liver. The remainder of ambroxol is metabolized in the liver, mainly by conjugation.

Acute and chronic diseases of the respiratory tract, accompanied by the release of viscous sputum:

  • acute and chronic bronchitis;
  • pneumonia;
  • chronic obstructive pulmonary disease;
  • bronchial asthma with difficulty in sputum discharge;
  • bronchiectasis.

Syrup (children's form of the drug).

Solution for oral administration and inhalation.

Instructions for use and dosage

The drug in tablet form is prescribed to adults 30 mg 3 times a day.

If necessary, to enhance the therapeutic effect, you can prescribe 60 mg 2 times a day. The tablets are taken after meals with liquid.

The drug in the form of a syrup of 15 mg/5 ml is prescribed to adults and children over 12 years of age, 10 ml (2 teaspoons) 3 times a day; children aged 6 to 12 years - 5 ml (1 teaspoon) 2-3 times a day; children aged 2 to 6 years are prescribed 2.5 ml (1/2 teaspoon) 3 times a day; children under 2 years old - 2.5 ml (1/2 teaspoon) 2 times a day.

The drug in the form of a syrup 30 mg/5 ml is prescribed to adults and children over 12 years of age 5 ml (1 teaspoon) 3 times a day; children aged 6 to 12 years - 2.5 ml (1/2 teaspoon) 2-3 times a day.

Taking the drug for more than 4-5 days is possible only under the supervision of a doctor.

Lazolvan in the form of syrup should be taken during meals with liquid.

Lazolvan in the form of an inhalation solution can be used with any modern inhalation device, except for evaporating inhalers. The drug is mixed with saline in a 1:1 ratio to achieve optimal air humidification in the respirator.

During inhalation, in order to avoid a cough reflex caused by a deep breath, the patient should breathe calmly. It is recommended to warm the inhaled solution to body temperature. Patients with bronchial asthma are recommended to take inhalations after taking bronchodilators.

  • heartburn;
  • dyspepsia;
  • nausea, vomiting;
  • diarrhea;
  • skin rash;
  • hives;
  • angioedema;
  • anaphylactic reactions (including anaphylactic shock).
  • 1st trimester of pregnancy;
  • hypersensitivity to the components of the drug.

Use during pregnancy and breastfeeding

Lazolvan penetrates the placental barrier.

Experimental studies on animals did not reveal direct or indirect adverse effects on pregnancy, embryonic, prenatal and postnatal development and childbirth.

Clinical studies during 28 weeks of pregnancy found no evidence of a negative effect of the drug on the fetus.

However, the usual precautions should be taken when using the drug during pregnancy. It is especially not recommended to take Lazolvan in the 1st trimester of pregnancy.

Ambroxol can be excreted in human milk. Therefore, it is not recommended to prescribe Lazolvan to nursing mothers. However, an adverse effect in newborns is unlikely.

Should not be used in combination with antitussives that impede the removal of sputum.

Lazolvan syrup (15 mg/5 ml) contains 10.5 g of sorbitol based on the maximum recommended daily dose (30 ml). Patients with rare hereditary fructose intolerance should not take this drug. It may also have a mild laxative effect.

Lazolvan syrup (30 mg/5 ml) contains 5 g of sorbitol based on the maximum recommended daily dose (20 ml). Patients with rare hereditary fructose intolerance should not take this drug.

Lazolvan tablets (30 mg) contain 684 mg of lactose based on the maximum recommended daily dose (120 mg). Patients with rare hereditary galactose intolerance, Lapp lactase deficiency or impaired glucose/galactose absorption should not take this drug.

Very rare cases of severe skin lesions have been reported, such as Stevens-Johnson syndrome and Lyell's syndrome; however, the relationship with the drug has not been proven. If the above syndromes develop, it is recommended to stop treatment and immediately seek medical help.

Simultaneous use with antitussive drugs leads to difficulty in sputum discharge while reducing cough.

Ambroxol increases the penetration of amoxicillin, cefuroxime, erythromycin, and doxycycline into the bronchial secretions.

Lazolvan is compatible with drugs that inhibit labor.

Analogues of the drug Lazolvan

Structural analogues of the active substance:

Source: http://instrukciya-otzyvy.ru/110-lazolvan-po-primeneniyu-analogi-tabletki-sirop-rastvor-dlya-ingalyaciy-pastilki-kashel-bronhit.html

Lazolvan

Lazolvan: instructions for use and reviews

Latin name: Lasolvan

ATX code: R05CB06

Active ingredient: ambroxol (ambroxol)

Manufacturer: Instituto De Angeli (Italy), Boehringer Ingelheim Ellas (Greece), Bolder Arzneimittel GmbH & Co. KG (Germany), Delpharm Reims (France)

Update of description and photo: 08/29/2017

Prices in pharmacies: from 156 rubles.

Lazolvan is an expectorant and mucolytic drug.

Release form and composition

Lazolvan is produced in the following dosage forms:

  • Lozenges: round, light brown, with the smell of peppermint (in blisters of 10 pcs., 1, 2 or 4 blisters in a cardboard box);
  • Tablets: round, slightly yellowish or white, flat on both sides, with beveled edges, on one side there is a separating line and the inscription “67C” embossed on both sides of it, on the other - the company symbol (in blisters of 10 pcs., 2 or 5 blisters in a cardboard box);
  • Syrup: almost colorless or colorless, almost transparent or transparent, with the smell of wild berries (15 mg/5 ml each) or strawberry smell (30 mg/5 ml each), slightly viscous (in dark glass bottles of 100, 200 or 250 ml per complete with or without a measuring cup, 1 bottle in a cardboard box);
  • Solution for oral administration and inhalation: transparent, slightly brownish or colorless (in dark glass bottles of 100 ml, complete with a dosing cup or beaker, 1 bottle in a cardboard box).

The composition of 1 lozenge Lazolvan includes:

  • Active substance: ambroxol – 15 mg (in the form of hydrochloride);
  • Auxiliary components: acacia gum – 850 mg, sorbitol – 307.4 mg, carion 83 (mannitol, sorbitol, hydrogenated hydrolyzed starch) – 614.8 mg, peppermint leaf oil – 10 mg, eucalyptus leaf oil – 2 mg, saccharin sodium – 1.8 mg, liquid paraffin (purified mixture of liquid saturated hydrocarbons) – 2.4 mg, purified water – 196.6 mg.

The composition of 1 tablet Lazolvan includes:

  • Active substance: ambroxol – 30 mg (in the form of hydrochloride);
  • Auxiliary components: lactose monohydrate – 171 mg, dried corn starch – 36 mg, colloidal silicon dioxide – 1.8 mg, magnesium stearate – 1.2 mg.

The composition of 5 ml of Lazolvan syrup includes:

  • Active substance: ambroxol – 15 or 30 mg (in the form of hydrochloride);
  • Auxiliary components (15/30 mg per 5 ml, respectively): benzoic acid - 8.5/8.5 mg, hydroxyethylcellulose (hyetellose) - 10/10 mg, acesulfame potassium - 5/5 mg, liquid sorbitol (non-crystallizing) - 1750/1750 mg, glycerol 85% – 750/750 mg, vanilla flavor – 3/3 mg, purified water – 3047.5/3031.5 mg, wild berry flavor PHL – 11 mg (for syrup 15 mg/5 ml) or strawberry-cream flavor PHL – 12 mg (for syrup 30 mg/5 ml).

The composition of 1 ml of solution for oral administration and inhalation of Lazolvan includes:

  • Active substance: ambroxol – 7.5 mg (in the form of hydrochloride);
  • Auxiliary components: citric acid monohydrate - 2 mg, sodium hydrogen phosphate dihydrate - 4.35 mg, sodium chloride - 6.22 mg, benzalkonium chloride - 0.225 mg, purified water - 989.705 mg.

Pharmacological properties

Pharmacodynamics

Research data show that ambroxol, which is the active component of Lazolvan, causes an increase in secretion in the respiratory tract. As a result of exposure to the drug, the production of pulmonary surfactant and ciliary activity are enhanced. These effects stimulate the flow and transport of mucus (mucociliary clearance), resulting in intense mucus discharge and cough relief. In the treatment of chronic obstructive pulmonary disease during long-term therapy with Lazolvan (for 2 months or more), the number of exacerbations decreased significantly. A significant decrease in the duration of exacerbations and the number of days of antibiotic therapy was recorded.

Pharmacokinetics

All dosage forms of immediate release ambroxol are characterized by rapid and almost complete absorption (a linear dependence of absorption on dose is observed). When taken orally, the maximum concentration of ambroxol in plasma is achieved after 60–150 minutes. Distribution volume – 552 l. The binding of ambroxol to plasma proteins in the therapeutic concentration range is approximately 90%.

When administered orally, the transition of the active substance from the blood to the tissues occurs quickly. The highest concentrations of ambroxol are observed in the lungs. About 30% of an oral dose undergoes a first pass process through the liver. Studies on human liver microsomes have proven that the predominant isoform is the CYP3A4 isoenzyme. It is responsible for the metabolism of the active substance to dibromanthranilic acid. The remaining amount is metabolized in the liver, mostly by glucuronidation and through partial degradation (approximately 10%) to dibromoantranilic acid and additional metabolites in small quantities. The terminal half-life is 10 hours. Total clearance is up to 660 ml/min, with about 8% of the total clearance being renal clearance. In studies using the radioactive tracer method, it was calculated that as a result of taking a single dose of ambroxol over the next 5 days, approximately 83% of the dose taken is excreted in the urine.

A clinically significant effect of gender and age on the pharmacokinetics of ambroxol has not been recorded, so there is no reason to select the dosage based on these characteristics.

Indications for use

Lazolvan is prescribed for the treatment of the following acute and chronic diseases of the respiratory tract, which occur with the release of viscous sputum:

  • Bronchiectasis;
  • Pneumonia;
  • Bronchitis in acute and chronic course;
  • Bronchial asthma, occurring with difficulty in sputum discharge;
  • Chronic obstructive pulmonary disease.

Contraindications

  • First trimester of pregnancy and lactation period;
  • Hypersensitivity to the components of the drug.

Lazolvan should be used with caution in pregnant women in the second and third trimesters, as well as in those with renal and/or liver failure.

Children, depending on the dosage form of Lazolvan, can take:

  • Lozenges and syrup 30 mg/5 ml: from 6 years;
  • Tablets: from 18 years of age.

The lozenges, based on the maximum recommended daily dose (90 mg), contain 3200 mg of sorbitol, so patients with rare hereditary fructose intolerance should not take Lazolvan in this dosage form.

Lazolvan in tablet form is contraindicated for patients with lactase deficiency, lactose intolerance and glucose-galactose malabsorption.

Lazolvan syrup should not be taken by patients with hereditary fructose intolerance.

Instructions for use of Lazolvan: method and dosage

Lazolvan is used orally or inhaled.

The drug can be taken orally regardless of the time of meal.

Lozenges should be slowly dissolved in the mouth, tablets should be taken with liquid, the solution can be diluted in juice, tea, milk or water.

As a rule, Lazolvan is prescribed orally:

  • Lozenges: adults and children over 12 years old – 3 times a day, 2 lozenges; children 6-12 years old – 2-3 times a day, 1 lozenge;
  • Tablets: 3 times a day, 1 tablet; to enhance the therapeutic effect, it is possible to increase the daily dose (2 times a day, 2 tablets);
  • Syrup 15 mg/5 ml: adults and children over 12 years old – 3 times a day, 10 ml; children 6-12 years old – 2-3 times a day, 5 ml; children 2-6 years old – 3 times a day, 2.5 ml; children under 2 years old – 2.5 ml 2 times a day;
  • Syrup 30 mg/5 ml: adults and children over 12 years old – 3 times a day, 5 ml; children 6-12 years old – 2-3 times a day, 2.5 ml;
  • Oral solution (1 ml = 25 drops): adults and children over 12 years old – 3 times a day, 100 drops; children 6-12 years old – 2-3 times a day, 50 drops; children 2-6 years old – 3 times a day, 25 drops; children under 2 years old – 2 times a day, 25 drops.

Inhalation Lazolvan is usually prescribed:

  • Adults and children over 6 years old – 1-2 inhalations of 2-3 ml of solution per day;
  • Children under 6 years old – 1-2 inhalations of 2 ml of solution per day.

For inhalation, you can use any modern equipment designed for this (except for steam inhalers). To ensure optimal hydration during inhalation, Lazolvan should be mixed with a 0.9% sodium chloride solution in a 1:1 ratio. Since during inhalation therapy a deep breath can lead to the development of a cough, inhalations must be carried out while maintaining a normal breathing rhythm. Before the procedure, it is recommended to warm the Lazolvan inhalation solution to body temperature. Patients with bronchial asthma are recommended to carry out inhalation after taking bronchodilator drugs, which will help avoid nonspecific irritation of the respiratory tract and their spasm.

If symptoms of the disease persist for 4-5 days from the start of taking Lazolvan, it is recommended to consult a doctor.

Side effects

As a rule, Lazolvan is well tolerated.

The following side effects may develop during therapy:

  • Gastrointestinal tract: often - nausea, decreased sensitivity in the esophagus or mouth; uncommon – diarrhea, dyspepsia, heartburn, vomiting, pain in the upper abdomen, dry mucous membrane of the throat and mouth;
  • Nervous system: often – disturbance of taste sensations;
  • Immune system, skin and subcutaneous tissues: rarely - urticaria, rash, angioedema, anaphylactic reactions (including anaphylactic shock), itching and other allergic reactions.

Overdose

Specific symptoms of Lazolvan overdose in humans have not been described.

There is evidence of a medical error and/or accidental overdose, as a result of which symptoms of side effects known for this drug were recorded: dyspepsia, nausea, vomiting, diarrhea, abdominal pain. In some cases, there is a need for symptomatic therapy.

Treatment: you should artificially induce vomiting, rinse the stomach for 1-2 hours after taking the drug. Symptomatic therapy is also indicated.

special instructions

Lazolvan should not be combined with antitussive drugs that impede the removal of sputum.

In patients with severe skin lesions (toxic epidermal necrolysis or Stevens-Johnson syndrome), the early phase may include fever, rhinitis, body pain, sore throat and cough. During symptomatic therapy, it is possible to erroneously prescribe mucolytic drugs such as Lazolvan. There are isolated reports of the detection of toxic epidermal necrolysis and Stevens-Johnson syndrome, which coincided with its administration, but there is no cause-and-effect relationship with the use of Lazolvan.

If the above syndromes develop, you should stop using the drug and immediately seek help from a doctor.

In case of functional disorders of the kidneys, Lazolvan can be used only as prescribed by a doctor.

1 tablet contains 162.5 mg of lactose, in the maximum daily dose (4 tablets) – 650 mg of lactose.

The sorbitol contained in the syrup may have a slight laxative effect. The maximum recommended daily dose of syrup contains 5 g (in 20 ml of syrup 30 mg/5 ml) or 10.5 g (in 30 ml of syrup 15 mg/5 ml) of sorbitol.

The solution for oral administration and inhalation contains the preservative benzalkonium chloride, which during inhalation can cause bronchospasm in patients with increased respiratory tract reactivity. The solution is not recommended to be mixed with alkaline solutions and cromoglycic acid. An increase in the pH value of the solution above 6.3 may lead to precipitation of the active substance or the appearance of opalescence.

Patients who follow a low-sodium diet should take into account that the recommended daily dose (for adults and children over 12 years of age) of Lazolvan in the form of a solution for oral administration and inhalation contains 42.8 mg of sodium.

Use during pregnancy and lactation

Ambroxol penetrates the placental barrier. Preclinical studies did not reveal any direct or indirect adverse effects of the drug on the course of pregnancy, embryonic/fetal, postnatal development and labor.

Extensive clinical experience with the use of the drug from the 28th week of pregnancy has shown no evidence of a negative effect of the drug on the fetus, however, when using Lazolvan during pregnancy, the usual precautions should be followed. The drug is not recommended to be taken in the first trimester of pregnancy. Use in the second or third trimesters is allowed only in cases where the possible risk to the fetus is lower than the potential benefit to the mother.

Ambroxol is excreted in breast milk. There is no data on the development of undesirable effects in children who were breastfed, however, it is not recommended to use Lazolvan during lactation.

Preclinical studies of ambroxol did not reveal any negative effects on fertility.

Use in childhood

When treating children under 12 months of age, Lazolvan is used only in the form of a solution. In such cases, it is necessary to ensure constant medical supervision.

According to the instructions, Lazolvan in the form of tablets is prohibited for use in the treatment of children under the age of 18 years, in the form of lozenges - up to 6 years.

For impaired renal function

In case of renal failure, the drug should be used with caution.

For liver dysfunction

In case of liver failure, the drug should be used with caution.

Drug interactions

There are no data on undesirable clinically significant interactions of Lazolvan with other drugs.

Lazolvan increases the penetration of drugs such as cefuroxime, amoxicillin and erythromycin into the bronchial secretions.

Analogs

Analogs of Lazolvan are: Ambroxol, Ambroxol Vramed, Ambrobene, Medox, Ambrohexal, Bronchorus, Halixol, Flavamed, Lazolvan Uno.

Terms and conditions of storage

Store in a place protected from light, out of reach of children.

  • Lozenges – 3 years at temperatures up to 30 °C;
  • Tablets – 5 years at temperatures up to 30 °C;
  • Syrup – 3 years at temperatures up to 25 °C;
  • Solution for oral administration and inhalation – 5 years at temperatures up to 25 °C.

Conditions for dispensing from pharmacies

Available without a prescription.

Reviews about Lazolvan

Reviews about Lazolvan are mostly positive. Users note that within a few days after taking the drug, there is an improvement in bronchitis and other diseases. According to reviews from parents, Lazolvan in the form of an inhalation solution and syrup has proven itself well in the treatment of children.

Also, some users report the development of side effects (diarrhea, allergic skin reactions).

Price for Lazolvan in pharmacies

The approximate price for Lazolvan is:

  • lozenges (20 pcs per pack) – 211 rubles;
  • tablets: 50 pcs. – 290 rub., 20 pcs. – 170 rub.;
  • syrup in 100 ml bottles: 15 mg/5 ml – 215 rubles, 30 mg/5 ml – 280 rubles;
  • solution for oral administration and inhalation 7.5 mg/ml in 100 ml bottles – 380 rub.

Lazolvan tablets 30 mg 20 pcs.

Lazolvan tab. 30mg n20

Lazolvan 15 mg No. 20 lozenges

Lazolvan 30 mg No. 20 tablets

Lazolvan tablets 30 mg n20

Lazolvan Max capsules 75 mg 10 pcs.

Lazolvan syrup 15 mg/5 ml 100 ml

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes and does not replace official instructions. Self-medication is dangerous to health!

Millions of bacteria are born, live and die in our intestines. They can only be seen under high magnification, but if they were put together, they would fit in a regular coffee cup.

In an effort to get the patient out, doctors often go too far. For example, a certain Charles Jensen in the period from 1954 to 1994. survived more than 900 operations to remove tumors.

Our kidneys are capable of purifying three liters of blood in one minute.

Scientists from Oxford University conducted a series of studies in which they came to the conclusion that vegetarianism can be harmful to the human brain, as it leads to a decrease in its mass. Therefore, scientists recommend not completely excluding fish and meat from your diet.

According to WHO research, talking on a mobile phone for half an hour every day increases the likelihood of developing a brain tumor by 40%.

The human brain weighs about 2% of the total body weight, but it consumes about 20% of the oxygen entering the blood. This fact makes the human brain extremely susceptible to damage caused by a lack of oxygen.

The highest body temperature was recorded in Willie Jones (USA), who was admitted to the hospital with a temperature of 46.5°C.

74-year-old Australian resident James Harrison has donated blood about 1,000 times. He has a rare blood type whose antibodies help newborns with severe anemia survive. Thus, the Australian saved about two million children.

You are more likely to break your neck if you fall off a donkey than if you fall off a horse. Just don't try to refute this statement.

The cough medicine “Terpinkod” is one of the top sellers, not at all because of its medicinal properties.

In order to say even the shortest and simplest words, we use 72 muscles.

The average life expectancy of left-handers is shorter than that of right-handers.

Research shows that women who drink several glasses of beer or wine per week have an increased risk of developing breast cancer.

Smiling just twice a day can lower your blood pressure and reduce the risk of heart attacks and strokes.

More than $500 million a year is spent on allergy medications in the United States alone. Do you still believe that a way to finally defeat allergies will be found?

Omissions, disagreements, maiden name... Women's jealousy is a mystery for psychologists. Today, scientists do not fully know all the mechanisms that give rise to this strong and ra.

Source: http://www.neboleem.net/lazolvan.php

What does Lazolvan help with? Instructions for use.

The drug belongs to the following groups:

Lazolvan is an effective expectorant and mucolytic agent, the main purpose of which is to treat diseases of the lungs and bronchi. It helps to enhance the action of enzymes that destroy mucus and reduce the viscosity of bronchial sputum, regulating the ratio of its components.

The positive effect of taking it is due to the active substance included in its composition - ambroxol hydrochloride. It activates the process of mucus removal by stimulating the activity of the epithelial cilia of the bronchi. The therapeutic effect of this drug is observed 30 minutes after administration and lasts for 6 to 12 hours.

Compound

The main active ingredient of this drug is ambroxol or ambroxol hydrochloride, and additional components are corn starch, silicon, lactose, magnesium stearate, water and various flavorings.

What does Lazolvan help with?

Doctors recommend taking this medication for various respiratory diseases accompanied by the formation of viscous sputum, including:

  • chronic or acute bronchitis;
  • bronchial asthma;
  • respiratory failure in newborns;
  • pneumonia;
  • bronchiectasis.

Doctors advise not to use this medication in cases such as:

  1. first trimester of pregnancy;
  2. liver or kidney failure;
  3. sensitivity to the components of the drug;
  4. lactation period.

To avoid possible allergic reactions due to taking this drug, read the list of contraindications in advance and, if necessary, consult your doctor.

Dosage regimen

The dosage of this medicine is determined by your doctor. It depends on the individual characteristics of your body, the pathology to which you are susceptible, as well as on the form of release of this medication.

  • The medicine in tablet form should be taken after meals with plenty of liquid. Adults need to drink 30 mg 3 times a day. To enhance the therapeutic effect, it is recommended to take 60 mg of Lazolvan 2 times a day.
  • Lazolvan in the form of syrup should be given to children whose age has exceeded the age mark of 12 years, and to adults, 10 ml 3 times a day, and to children from 6 to 12 years old – 5 ml. Children whose age ranges from 2 to 6 years are recommended to take 2.5 ml 3 times a day, and children under 2 years old - 2.5 ml 2 times a day.

The average duration of treatment is 4 – 5 days. After this period, Lazolvan can be taken only under medical supervision.

Side effect

This drug has the following side effects, which may occur with excessive use of Lazolvan, as well as in cases of individual intolerance to this drug:

  • cessation of normal functioning of internal organs;
  • discomfort in the gastrointestinal tract: heartburn, nausea, pain, etc.;
  • allergic manifestations of various types.

Drug interactions and special instructions for use

Doctors do not recommend combining this medication with other drugs that make it difficult to remove mucus. It is also undesirable to take Lazolvan with amoxicillin or erythromycin, since their increased penetration into bronchial secretions is observed.

If you treat patients with skin diseases, Stevens-Johnson syndrome, with this medication, they may experience the following adverse reactions:

  • severe body pain;
  • cough;
  • inflammatory processes in the throat;
  • elevated body temperature.

If the above-mentioned symptoms develop and the patient’s well-being worsens while taking this drug, it is recommended to stop treatment and immediately inform your doctor about what is happening.

Take care of yourself and be healthy!

Look at similar drugs:

Lazolvan: reviews

Before using medications, consult your doctor!

Source: http://otchegoshka.ru/lazolvan-ot-chego.html

What does Lazolvan help with?

Lazolvan is an effective medication that helps to quickly cope with various inflammatory diseases of the respiratory tract, accompanied by a significant disturbance in the discharge of sputum and mucus.

This drug has pronounced expectorant, secretolytic, as well as mucolytic (antitussive) effects.

Regular use of Lazolvan can significantly reduce the viscosity of sputum in the respiratory tract, while normalizing breathing, as well as reducing possible coughing of varying intensity.

The main active medicinal substance of this drug is Ambroxol, which has good expectorant and antitussive properties.

Main indications for use of Lazolvan:

  • acute or chronic form of bronchitis;
  • bronchiectasis;
  • pneumonia (pneumonia);
  • laryngotracheitis;
  • chronic obstructive pulmonary disease;
  • bronchial asthma, which is accompanied by a significant disturbance in the discharge of sputum and mucus from the respiratory tract.

Attention: before using Lazolvan, it is recommended to consult with a qualified pulmonologist or therapist!

The drug is produced in the form of soluble tablets, as well as syrup for internal use.

How to drink Lazolvan?

The daily dose of Lazolvan for adults is 1 t. 2-3 r. a day after meals, with plenty of water.

The minimum interval between doses is 4-5 hours, while the maximum daily dose should not exceed more than 3-4 tons.

For children, this drug is usually prescribed in syrup, depending on age and the specific inflammatory disease of the respiratory system.

For adults and children over 14 years of age, the daily dose of Lazolvan in syrup is 10 ml. 2-3 r. for a day. The average course of treatment is 7-10 days, depending on the severity of a particular disease.

Recommended doses for children:

  • 1-2 years: 2-2.5 ml. 1-2 r. for a day;
  • 3-5 years: 2.5 ml. no more than 2-3 rubles/day;
  • 6-10 years: 5 ml. 2 rubles/day;
  • 11-14 years: 5-6 ml. 2-3 rubles/day.

If necessary, a second course of treatment with Lazolvan is possible after about 2-3 months only after mandatory consultation with your doctor!

Contraindications to the use of Lazolvan

  • hypersensitivity (increased sensitivity of the body to the main active ingredient of the drug);
  • pregnancy and lactation (breastfeeding);
  • acute renal or liver failure.

Side effects of Lazolvan

As a rule, this drug is well tolerated by patients after long-term use, but sometimes minor adverse reactions may occur in the form of:

  • local allergic reactions on the skin (urticaria, increased skin itching, erythema);
  • nausea or vomiting (occurs extremely rarely, mainly with a significant overdose of the drug);
  • diarrhea;
  • minor pain in the epigastric (epigastric) region of the abdomen;
  • dry mouth.

If any of the above side effects develop, it is recommended to consult your doctor!

In this article, we looked at what Lazolvan helps with, as well as how to take it correctly.

Read also:

Share on social networks

Comments

Add a comment

Categories:

Advertising

Good to know:

Join us!

Let's improve the site!

Remember, self-medication is dangerous to your health! Consult your doctor

Source: http://in4health.ru/ot-chego-pomogaet-lazolvan.html

Lasolvan ® (Lasolvan ® )

Active substance:

Content

Pharmacological group

Nosological classification (ICD-10)

3D images

Compound

Description of the dosage form

Solution for oral administration and inhalation: clear, colorless or slightly brownish.

pharmachologic effect

Pharmacodynamics

Studies have shown that ambroxol, the active ingredient in Lazolvan ®, increases secretion in the respiratory tract. It enhances the production of pulmonary surfactant and stimulates ciliary activity. These effects result in increased mucus flow and transport (mucociliary clearance). Increasing mucociliary clearance improves sputum discharge and relieves cough. In patients with COPD, long-term therapy with Lazolvan ® (for at least 2 months) led to a significant reduction in the number of exacerbations. There was a significant decrease in the duration of exacerbations and the number of days of antibiotic therapy.

Pharmacokinetics

All dosage forms of immediate release ambroxol are characterized by rapid and almost complete absorption with a linear dose dependence in the therapeutic concentration range. Cmax when taken orally is achieved within 1–2.5 hours .

V d - 552 l. In the therapeutic concentration range, binding to plasma proteins is approximately 90%.

The transition of ambroxol from the blood to tissues when administered orally occurs quickly. The highest concentrations of the active component of the drug are observed in the lungs.

Approximately 30% of an oral dose is subject to first pass effects through the liver. Studies on human liver microsomes have shown that CYP3A4 is the predominant isoform responsible for the metabolism of ambroxol to dibromoantranilic acid. The remainder of ambroxol is metabolized in the liver, mainly by glucuronidation and partial degradation to dibromoanthranilic acid (approximately 10% of the administered dose), as well as a small number of additional metabolites.

The terminal half- of ambroxol is 10 hours. The total clearance is within 660 ml/min, renal clearance accounts for approximately 8% of the total clearance. Using a radioactive tracer, it was estimated that after taking a single dose of the drug over the next 5 days, about 83% of the dose taken is excreted in the urine. No clinically significant effect of age and gender on the pharmacokinetics of ambroxol was found, so there is no basis for selecting the dosage based on these characteristics.

Indications of the drug Lazolvan ®

Acute and chronic diseases of the respiratory tract with the release of viscous sputum:

acute and chronic bronchitis;

chronic obstructive pulmonary disease;

bronchial asthma with difficulty in sputum discharge;

Contraindications

hypersensitivity to ambroxol or other components of the drug;

pregnancy (first trimester).

With caution: II–III trimester of pregnancy; renal and/or liver failure.

Use during pregnancy and breastfeeding

Ambroxol penetrates the placental barrier. Preclinical studies have not revealed direct or indirect adverse effects on pregnancy, embryonic/fetal, postnatal development and labor.

Extensive clinical experience with the use of ambroxol after the 28th week of pregnancy has not found evidence of a negative effect of the drug on the fetus. However, normal precautions must be taken when using the medicine during pregnancy.

It is especially not recommended to take Lazolvan ® in the first trimester of pregnancy. In the second and third trimesters of pregnancy, the use of the drug is possible only if the potential benefit to the mother outweighs the potential risk to the fetus.

Ambroxol can be excreted in breast milk. Despite the fact that no undesirable effects were observed in breast-fed children, it is not recommended to use the drug Lazolvan ® solution for oral administration and inhalation during lactation. Preclinical studies of ambroxol did not reveal any negative effects on fertility.

Side effects

From the gastrointestinal tract: often (1–10%) - nausea, decreased sensitivity in the oral cavity or pharynx; uncommon (0.1–1%) - dyspepsia, vomiting, diarrhea, abdominal pain, dry mouth; rarely (0.01–0.1%) - dry throat.

Immune system disorders, damage to the skin and subcutaneous tissues: rarely (0.01–0.1%) - skin rash, urticaria; anaphylactic reactions (including anaphylactic shock)*, angioedema*, itching*, hypersensitivity*.

From the nervous system: often (1–10%) - dysgeusia (impaired sense of taste).

*These adverse reactions were observed with widespread use of the drug; with a 95% probability, the frequency of these adverse reactions is uncommon (0.1–1%), but possibly lower; the exact frequency is difficult to estimate, because they were not noted in clinical studies.

Interaction

No clinically significant adverse interactions with other drugs have been reported. Increases the penetration of amoxicillin, cefuroxime, and erythromycin into the bronchial secretions.

Directions for use and doses

Inside, regardless of food intake. Oral administration (1 ml = 25 drops).

Adults and children over 12 years old: 4 ml (= 100 drops) 3 times a day: children from 6 to 12 years old: 2 ml (= 50 drops) 2-3 times a day; from 2 to 6 years: 1 ml (= 25 drops) 3 times a day; up to 2 years: 1 ml (= 25 drops) 2 times a day. Drops can be diluted in water, tea, juice or milk.

Adults and children over 6 years of age: 1–2 inhalations of 2–3 ml of solution per day; children under 6 years of age: 1–2 inhalations of 2 ml of solution per day. Lazolvan ® , a solution for inhalation, can be used using any modern equipment for inhalation (except for steam inhalers). To achieve maximum hydration during inhalation, the drug is mixed with 0.9% sodium chloride solution in a 1:1 ratio. Since during inhalation therapy a deep breath can provoke a cough, inhalations should be carried out in normal breathing mode. Before inhalation, it is usually recommended to warm the inhalation solution to body temperature. Patients with bronchial asthma are recommended to carry out inhalation after taking bronchodilators to avoid nonspecific irritation of the respiratory tract and their spasm.

If symptoms of the disease persist within 4-5 days from the start of taking the drug, it is recommended to consult a doctor.

Overdose

Specific symptoms of overdose in humans have not been described. There are reports of accidental overdose and/or medical error, as a result of which symptoms of known side effects of the drug Lazolvan ® were observed: nausea, dyspepsia, vomiting, diarrhea, abdominal pain.

Treatment: induction of vomiting, gastric lavage in the first 1–2 hours after taking the drug; symptomatic therapy.

special instructions

It should not be combined with antitussives that make it difficult to remove sputum.

The solution contains the preservative benzalkonium chloride, which, when inhaled, may cause bronchospasm in sensitive patients with increased respiratory tract reactivity.

The drug Lazolvan ®, a solution for oral administration and inhalation, is not recommended to be mixed with cromoglycic acid and alkaline solutions.

An increase in the pH value of the solution above 6.3 may cause precipitation of ambroxol hydrochloride or the appearance of opalescence.

Patients on a hyposodium diet should take into account that Lazolvan ®, solution for oral administration and inhalation, contains 42.8 mg of sodium in the recommended daily dose (12 ml) for adults and children over 12 years of age.

There are isolated reports of severe skin lesions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, coinciding with the administration of expectorants such as ambroxol hydrochloride. In most cases, they can be explained by the severity of the underlying disease and/or concomitant therapy.

Patients with Stevens-Johnson syndrome or toxic epidermal necrolysis may present with fever, body aches, rhinitis, cough, and sore throat in the early phase. With symptomatic treatment, it is possible to erroneously prescribe anti-cold medications. If new lesions of the skin and mucous membranes appear, it is recommended to stop treatment with ambroxol and immediately seek medical help.

If renal function is impaired, Lazolvan ® should be used only on the recommendation of a doctor.

The effect of the drug on the ability to drive vehicles and machinery. No cases of influence of the drug Lazolvan ® on the ability to drive vehicles and machinery have been identified. Studies on the effect of the drug on the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions have not been conducted.

Release form

Solution for oral administration and inhalation, 7.5 mg/ml. 100 ml in amber glass bottles with a PE dropper and a polypropylene screw cap with tamper evident. Each bottle is placed in a cardboard box and a measuring cup.

Manufacturer

Instituto de Angeli S.R.L., Reggello, Prulli, 103/C, Florence, Italy.

The legal entity in whose name the registration certificate was issued. JSC Sanofi Russia, Russia.

Consumer complaints should be sent to the address in Russia: Moscow, st. Tverskaya, 22.

Tel: ; Fax: .

Conditions for dispensing from pharmacies

Storage conditions for the drug Lazolvan ®

Keep out of the reach of children.

Shelf life of the drug Lazolvan ®

Do not use after the expiration date stated on the package.

Synonyms of nosological groups

Prices in Moscow pharmacies

The information is intended solely for comparing prices in stationary pharmacies operating in accordance with Article 55 of the Federal Law “On the Circulation of Medicines” dated April 12, 2010 N 61-FZ.

tablets 30 mg, 20 pcs.

Boehringer Ingelheim International (Germany)

tablets 30 mg, 50 pcs.

Boehringer Ingelheim International (Germany)

syrup 15 mg/5 ml, 1 pc.

Boehringer Ingelheim International (Germany)

syrup 15 mg/5 ml, 1 pc.

Boehringer Ingelheim International (Germany)

syrup 30 mg/5 ml, 1 pc.

Boehringer Ingelheim International (Germany)

syrup 30 mg/5 ml, 1 pc.

Boehringer Ingelheim International (Germany)

syrup 30 mg/5 ml, 1 pc.

Boehringer Ingelheim International (Germany)

solution for oral administration and inhalation 7.5 mg/ml, 1 pc.

Boehringer Ingelheim International (Germany)

solution for oral administration and inhalation 7.5 mg/ml, 1 pc.

Boehringer Ingelheim International (Germany)

lozenges 15 mg, 20 pcs.

Boehringer Ingelheim International (Germany)

Leave your comment

Current information demand index, ‰

Opinion of “Doctors of the Russian Federation” about the drug Lazolvan ®

Registered prices of vital and essential drugs

  • First aid kit
  • Online store
  • About company
  • Contacts
  • Publisher contacts:
  • Email:
  • Address: Russia, Moscow, st. 5th Magistralnaya, no. 12.

When quoting information materials published on the pages of the website www.rlsnet.ru, a link to the source of information is required.

©. REGISTER OF MEDICINES OF RUSSIA ® RLS ®

All rights reserved

Commercial use of materials is not permitted

Information intended for healthcare professionals

Source: http://www.rlsnet.ru/tn_index_id_3925.htm

Lazolvan: instructions for use

Lazolvan is a drug from the group of mucolytics with a pronounced expectorant effect.

Release form and composition of the medicinal product

Lazolvan is available in the form of a solution for inhalation and oral administration in 100 ml dark glass bottles. The box with the drug contains a measuring cup for easy dosing, and the bottle itself is equipped with a special nozzle in the form of a dropper. Detailed instructions are included with the drug.

The contents of the bottle are transparent, have no color or any strong odor, let's say the solution has a brownish tint.

The main active ingredient of the drug is Ambroxol hydrochloride; 1 ml of solution contains 7.5 mg of this component. The auxiliary agents include sodium hydrogen phosphate dihydrate, purified water, and citric acid monohydrate.

Pharmacological properties of the solution

Lazolvan solution is an expectorant from the group of mucolytics.

The active ingredient of the drug, Ambroxol, increases mucus production in the respiratory tract and facilitates the process of mucus discharge due to its significant dilution. While using this drug, patients experience a productive wet cough.

In patients with chronic obstructive pulmonary disease, long-term therapy with Lazolvan solution led to a significant reduction in the frequency of disease relapses. Thanks to this drug, patients were able to reduce the duration and dose of treatment with antibiotics and antibacterial drugs.

Indications for use

The main indications for prescribing Lazolvan solution are the following conditions:

  • Inflammatory processes of the bronchial mucosa, accompanied by an unproductive, paroxysmal dry cough;
  • Cough due to pneumonia;
  • Bronchiectasis with the aim of facilitating and improving the discharge of pathological sputum;
  • Bronchial asthma during the absence of acute attacks to facilitate the discharge of sputum and reduce its viscosity.

Contraindications

Before starting therapy with Lazolvan, you should carefully read the accompanying instructions. The solution has the following contraindications for use:

  • Pregnancy in the 1st trimester;
  • Breastfeeding period;
  • Age in children under 2 years due to lack of clinical experience;
  • Simultaneous therapy with drugs that inhibit the cough center;
  • Individual intolerance to the components of the drug;
  • Whooping cough with reprises.

Lazolvan solution should be used with particular caution in patients with severe renal and liver failure and pregnant women in the 2nd and 3rd trimesters.

Directions for use and dosage

When administered orally, the drops are first diluted in a small amount of water, juice or tea. The medicine is taken regardless of food. 1 ml of the drug contains 25 drops.

According to the instructions, patients over 12 years of age and adults are prescribed 100 drops of solution 3 times a day.

Children from 6 to 12 years old are prescribed 50 drops of the drug 2-3 times a day, which is associated with the severity of the pathological process.

When using the solution for inhalation, the drug is poured into an inhaler or nebulizer at the rate of 2 ml of solution + 2 ml of isotonic sodium chloride solution, due to which the airways are moistened and the maximum therapeutic effect is achieved. Inhalations are carried out 1 to 3 times a day, depending on the severity of the clinical symptoms of the disease.

During inhalation, the patient should breathe normally, since taking deep breaths intentionally can provoke a severe coughing attack. Before inhalation, the drug should be warmed to body temperature.

The duration of treatment depends on the severity of the cough, but, as a rule, does not exceed 7 days. If no improvement is observed after 3-4 days from the start of treatment, the patient should consult a doctor for a comprehensive examination to determine the nature of the cough.

Use during pregnancy and breastfeeding

In the first trimester of pregnancy, treatment with Lazolvan is not carried out. Clinical trials have not revealed the teratogenic or embryotoxic effect of Ambroxol on the fetus, however, the active substance easily penetrates the placental barrier and it is unknown how this may affect the process of formation of the internal organs of the fetus.

In the 2nd and 3rd trimesters of pregnancy, treatment with the drug is possible only if the expected therapeutic effect for the mother and its benefits outweigh the likelihood of complications from the fetus.

Ambroxol is excreted in breast milk, so treatment with this drug is not recommended for nursing mothers during breastfeeding. If therapy is necessary, a woman should consider stopping lactation.

Adverse reactions

When the indicated therapeutic doses were observed, no negative reactions to the drug were observed. Persons with increased individual sensitivity may develop the following side effects:

  • From the digestive system - nausea, stomach pain, increased salivation, changes in appetite, vomiting, diarrhea, increased gas formation in the intestines;
  • Allergic reactions - rash and scratching on the skin, urticaria, in rare cases, the development of angioedema, allergic rhinitis or bronchospasm;
  • With long-term use of the drug, patients experienced a change in taste sensations (dulling of taste).

Overdose

Cases of overdose with Lazolvan have not been described in medicine, however, when the drug is abused, patients experience an increase in the above-described side effects and the development of dyspepsia.

If nausea and vomiting occur when the recommended dose is exceeded, the patient is given activated charcoal. If necessary, symptomatic treatment is provided.

Interaction of the drug with other drugs

The drug Lazolvan is strictly forbidden to be combined simultaneously with therapy with antitussives - drugs that have a direct effect on the cough center in the medulla oblongata.

Under the influence of Ambroxol, the therapeutic effect of antibiotics and antibacterial drugs increases, as a result of which it may be necessary to reduce their dose and duration of treatment.

special instructions

The Lazolvan solution contains benzalkonium chloride, a substance that, when inhaled during inhalation, can lead to the development of bronchospasm in hypersensitive patients.

In case of kidney disease with severe dysfunction of the organ, treatment with Lazolvan solution is possible only after consultation with a doctor.

In recommended therapeutic doses, the solution does not have a negative effect on the functioning of the central nervous system and does not inhibit the speed of psychomotor reactions.

Lazolvan analogues

The following drugs have a therapeutic effect similar to Lazolvan solution:

  • Ambrobene syrup;
  • Mucolvan solution for inhalation;
  • Ambroxol syrup;
  • Flavamed syrup;
  • Bromhexine tablets;
  • Bronchovern drops;
  • Bronchoxol solution.

Conditions of release and storage

Lazolvan solution can be purchased in pharmacies without a prescription from a doctor. It is recommended to store the medicine away from children at an optimal temperature of no higher than 25 degrees Celsius. The shelf life of the product is 3 years from the date of manufacture; after this period the medicine cannot be used.

Lazolvan price

On average, the cost of the drug Lazolvan in the form of a solution for oral administration and inhalation in Moscow pharmacies is 380 rubles.

Source: http://bezboleznej.ru/lazolvan